Jarrod Marto, Ph.D., is a Principal Investigator at the Dana-Farber Cancer Institute in the Departments of Cancer Biology and Oncologic Pathology with a joint appointment as Associate Professor of Pathology at Brigham and Women’s Hospital and Harvard Medical School. Since 2006 Dr. Marto has served as Director of the Blais Proteomics Center at Dana-Farber and is also an active member of the Chemical Biology Program. Dr. Marto is internationally recognized for his expertise in the development and use of state-of-the-art mass spectrometry and other bioanalytical techniques to understand how genomic alterations as well as the activity of chemical probes or clinical drugs manifest at the level of individual targets, signaling pathways, or other compartments throughout the functional proteome. His longstanding collaboration with Dana-Farber colleague and Entact co-founder Dr. Sara Buhrlage has fostered development of a purpose-built platform to accelerate design and characterization of new chemical probes targeting the family of deubiquitinases, or DUBs. Building on these results, Drs. Marto and Buhrlage recently launched the Dana-Farber Center for Emergent Drug Targets.

Dr. Marto has authored nearly 200 peer-reviewed papers across the fields of bioanalytical chemistry, scientific instrumentation, mass informatics, chemical biology and cancer cell signaling. In addition, he serves on the Scientific Advisory Board of 908 Devices and holds multiple patents spanning analytical science, advanced instrumentation, and cancer therapeutics. Dr. Marto earned his Ph.D. in analytical chemistry with Alan Marshall at The Ohio State University and went on to postdoctoral studies with Don Hunt at the University of Virginia. Dr. Marto joined the faculty at Dana-Farber in 2004.